Varian releases planning tool

Article

Radiotherapy giant Varian Medical Systems has begun marketing its latest treatment planning software for brachytherapy.

Radiotherapy giant Varian Medical Systems has begun marketing its latest treatment planning software for brachytherapy. VariSeed 7.0 helps physicians accurately deliver precise doses by providing access to real-time images generated during the implantation of radioactive seeds. The use of these seeds to treat prostate cancer has become increasingly common, producing results comparable to radical prostatectomy but with a lower risk of side effects such as impotence and incontinence. With VariSeed 7.0, radiation oncologists can generate a treatment plan, use it to implant the seeds, and see how the radiation dose will develop within the patient's anatomy while the patient is still in the operating room. This allows for fine-tuning and more precise adjustments on the spot, according to the company. VariSeed 7.0 also introduces the ability to superimpose different kinds of diagnostic images; SPECT, for example, can demonstrate the extent of disease, while CT and ultrasound show anatomy and positioning.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.